

INFORMATION DISCLOSURE STATEMENT

Docket No.: LA24a

Sheet $\underline{1}$ of $\underline{1}$

Serial No.:

09/391,053

Group: 1614

Applicant:

Jeffrey A. Robl et al

Filing Date:

09/07/99

U.S. PATENT DOCUMENTS

Examiner		Document	Date	Name	Class	Sub-	Filing
Initial		Number	Date		Ciass	class	Date
MMS	AA	4,001,228	01/04/77	Mattalia			
	AB	4,051,250	09/27/77	Dahm et al			
	AC	5,187,188	02/16/93	Meanwell			
	AD	5,218,124	06/08/93	Failli et al			
	AE	5,262,540	11/16/93	Meanwell	<u> </u>		
	AF	5,348,969	09/20/94	Romine et al 🗸			
. [AG	5,362,879	11/08/94	Meanwell			
MB	AH	5,380,854	01/10/95	Romine et al			
Ws	AI	5,403,852	04/04/95	Barreau et al			
mr	AJ	5,599,770	02/04/97	Kubota et al			
	AK						

FOREIGN PATENT DOCUMENTS

Examiner		Document	Date	Country	Class	Sub-	Filing Date
Initial		Number				class	Date
4.46	AL	2.1.56.486	01/06/73	France (English Abstract			
MB-		_		attached)			
	AM	2.647.676	07/12/90	France (English Abstract			
				attached)			
MB	AN	WO92/04334	19/03/92	PCT			
MB-	AO	WO95/17393	29/06/95	PCT			
	AP						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	OTHER (Including Author, Title, Date, Tertificant Tages, etc.)
Mr V AQ	Hotamisligil, G.S. et al, "Uncoupling of Obesity from Insulin Resistance Through a Targeted Mutation in aP2, the Adipocyte Fatty Acid Binding Protein", Science, Vo. 274, Nov. 22, 1996, pp 1377-1379.
MR AR	Mai, A. et al, "Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: Novel Non-Nucleoside Reverse Transcriptase Inhibitors of the S-DABO Series", J. Med. Chem., 1997, 40, 1447-1454
M5 - AS	Dialog Alert DBDR928, Jan. 2, 1997, Pharmaprojects No. 5149
AT	
AU	
AV	
. AW	
AX	
AY	
AZ	

Myind Bille

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.